Novel activities by ebolavirus and marburgvirus interferon antagonists revealed using a standardized in vitro reporter system

Virology

Volumn 501, Issue , 2017, Pages 147-165

  Guito, Jonathan C ^a   Albariño, César G ^a   Chakrabarti, Ayan K ^a   Towner, Jonathan S ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Ebolavirus; Filoviral interferon antagonists; Filoviruses; Innate immune response; Interferon pathway; Marburgvirus; Neglected pathogens; Viral immune evasion; Viral protein function; Virus host interactions

Indexed keywords

BETA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; PROTEIN VP24; PROTEIN VP35; PROTEIN VP40; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; VIRAL PROTEIN;

ARTICLE; BUNDIBUGYO VIRUS; CONTROLLED STUDY; CYTOKINE RELEASE; EBOLAVIRUS; EMBRYO; HUMAN; HUMAN CELL; IN VITRO STUDY; MARBURGVIRUS; NONHUMAN; PRIORITY JOURNAL; RAVN VIRUS; REPORTER GENE; RESTON VIRUS; SIGNAL TRANSDUCTION; SUDAN VIRUS; TAI FOREST VIRUS; VIRUS VIRULENCE; ANIMAL; ANTAGONISTS AND INHIBITORS; EBOLA HEMORRHAGIC FEVER; GENETICS; HOST PATHOGEN INTERACTION; MARBURG HEMORRHAGIC FEVER; METABOLISM; VIROLOGY;

ANIMALS; EBOLAVIRUS; GENES, REPORTER; HEMORRHAGIC FEVER, EBOLA; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERONS; MARBURG VIRUS DISEASE; MARBURGVIRUS; VIRAL PROTEINS;

EID: 85000577846     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2016.11.015     Document Type: Article

References (86)

1. Aggarwal, B.B., Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol. 3:9 (2003), 745–756.
2. Albariño, C.G., Wiggleton Guerrero, L., Spengler, J.R., Uebelhoer, L.S., Chakrabarti, A.K., Nichol, S.T., et al. Recombinant Marburg viruses containing mutations in the IID region of VP35 prevent inhibition of host immune responses. Virology 476 (2015), 85–91.
3. Amman, B.R., Carroll, S.A., Reed, Z.D., Sealy, T.K., Balinandi, S., Swanepoel, R., et al. Seasonal pulses of Marburg virus circulation in juvenile Rousettus aegyptiacus bats coincide with periods of increased risk of human infection. PLoS Pathog., 8(10), 2012, e1002877.
4. Amman, B.R., Nyakarahuka, L., McElroy, A.K., Dodd, K.A., Sealy, T.K., Schuh, A.J., et al. Marburgvirus resurgence in Kitaka Mine bat population after extermination attempts, Uganda. Emerg. Infect. Dis. 20:10 (2014), 1761–1764.
5. Amman, B.R., Jones, M.E., Sealy, T.K., Uebelhoer, L.S., Schuh, A.J., Bird, B.H., et al. Oral shedding of Marburg virus in experimentally infected Egyptian fruit bats (Rousettus aegyptiacus). J. Wildl. Dis. 51:1 (2015), 113–124.
6. Balachandran, S., Beg, A.A., Defining emerging roles for NF-kappaB in antivirus responses: revisiting the interferon-beta enhanceosome paradigm. PLoS Pathog., 7(10), 2011, e1002165.
7. Bale, S., Julien, J.P., Bornholdt, Z.A., Kimberlin, C.R., Halfmann, P., Zandonatti, M.A., et al. Marburg virus VP35 can both fully coat the backbone and cap the ends of dsRNA for interferon antagonism. PLoS Pathog., 8(9), 2012, e1002916.
8. Basler, C.F., Innate immune evasion by filoviruses. Virology 479–480 (2015), 122–130.
9. Basler, C.F., Wang, X., Mühlberger, E., Volchkov, V., Paragas, J., Klenk, H.D., et al. The Ebola virus VP35 protein functions as a type I IFN antagonist. Proc. Natl. Acad. Sci. USA 97:22 (2000), 12289–12294.
10. Basler, C.F., Mikulasova, A., Martinez-Sobrido, L., Paragas, J., Mühlberger, E., Bray, M., et al. The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J. Virol. 77:14 (2003), 7945–7956.
11. Bird, B.H., Maartens, L.H., Campbell, S., Erasmus, B.J., Erickson, B.R., Dodd, K.A., et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J. Virol. 85:24 (2011), 12901–12909.
12. Bosio, C.M., Aman, M.J., Grogan, C., Hogan, R., Ruthel, G., Negley, D., et al. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. J. Infect. Dis. 188:11 (2003), 1630–1638.
13. Bukreyev, A.A., Chandran, K., Dolnik, O., Dye, J.M., Ebihara, H., Leroy, E.M., et al. Discussions and decisions of the 2012–2014 international committee on taxonomy of viruses (ICTV) Filoviridae study group, January 2012–June 2013. Arch. Virol. 159:4 (2014), 821–831.
14. Burk, R., Bollinger, L., Johnson, J.C., Wada, J., Radoshitzky, S.R., Palacios, G., et al. Neglected filoviruses. FEMS Microbiol. Rev., 2016.
15. Cárdenas, W.B., Evasion of the interferon-mediated antiviral response by filoviruses. Viruses 2:1 (2010), 262–282.
16. Cárdenas, W.B., Loo, Y.M., Gale, M. Jr., Hartman, A.L., Kimberlin, C.R., Martinez-Sobrido, L., et al. Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J. Virol. 80:11 (2006), 5168–5178.
17. Carroll, S.A., Towner, J.S., Sealy, T.K., McMullan, L.K., Khristova, M.L., Burt, F.J., et al. Molecular evolution of viruses of the family Filoviridae based on 97 whole-genome sequences. J. Virol. 87:5 (2013), 2608–2616.
18. Chakraborty, S., Rao, B., Asgeirsson, B., Dandekar, A., Correlating the ability of VP24 protein from Ebola and Marburg viruses to bind human karyopherin to their immune suppression mechanism and pathogenicity using computational methods. F1000Research, 2014.
19. Chang, T.H., Kubota, T., Matsuoka, M., Jones, S., Bradfute, S.B., Bray, M., et al. Ebola Zaire virus blocks type I interferon production by exploiting the host SUMO modification machinery. PLoS Pathog., 5(6), 2009, e1000493.
20. Choi, J.H., Jonsson-Schmunk, K., Qiu, X., Shedlock, D.J., Strong, J., Xu, J.X., et al. A single dose respiratory recombinant adenovirus-based vaccine provides long-term protection for non-human primates from lethal Ebola infection. Mol. Pharm. 12:8 (2015), 2712–2731.
21. Clifton, M.C., Bruhn, J.F., Atkins, K., Webb, T.L., Baydo, R.O., Raymond, A., et al. High-resolution crystal Structure of dimeric VP40 from Sudan ebolavirus. J. Infect. Dis. 212:Suppl. 2 (2015), S167–S171.
22. Cong, Q., Pei, J., Grishin, N.V., Predictive and comparative analysis of Ebolavirus proteins. Cell Cycle 14:17 (2015), 2785–2797.
23. Dunham, E.C., Banadyga, L., Groseth, A., Chiramel, A.I., Best, S.M., Ebihara, H., et al. Assessing the contribution of interferon antagonism to the virulence of West African Ebola viruses. Nat. Commun., 6, 2015, 8000.
24. Edwards, M.R., Basler, C.F., Marburg virus VP24 protein relieves suppression of the NF-kappaB pathway through interaction with Kelch-like ECH-associated protein 1. J. Infect. Dis. 212:Suppl. 2 (2015), S154–S159.
25. Edwards, M.R., Liu, G., Mire, C.E., Sureshchandra, S., Luthra, P., Yen, B., et al. Differential regulation of interferon responses by Ebola and Marburg virus VP35 proteins. Cell Rep. 14:7 (2016), 1632–1640.
26. Feagins, A.R., Basler, C.F., The VP40 protein of Marburg virus exhibits impaired budding and increased sensitivity to human tetherin following mouse adaptation. J. Virol. 88:24 (2014), 14440–14450.
27. Feagins, A.R., Basler, C.F., Lloviu virus VP24 and VP35 proteins function as innate immune antagonists in human and bat cells. Virology 485 (2015), 145–152.
28. García, M.A., Gil, J., Ventoso, I., Guerra, S., Domingo, E., Rivas, C., et al. Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol. Mol. Biol. Rev. MMBR 70:4 (2006), 1032–1060.
29. García-Dorival, I., Wu, W., Dowall, S., Armstrong, S., Touzelet, O., Wastling, J., et al. Elucidation of the Ebola virus VP24 cellular interactome and disruption of virus biology through targeted inhibition of host-cell protein function. J. Proteome Res. 13:11 (2014), 5120–5135.
30. Gitlin, L., Barchet, W., Gilfillan, S., Cella, M., Beutler, B., Flavell, R.A., et al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl. Acad. Sci. USA 103:22 (2006), 8459–8464.
31. Halfmann, P., Neumann, G., Kawaoka, Y., The Ebolavirus VP24 protein blocks phosphorylation of p38 mitogen-activated protein kinase. J. Infect. Dis. 204:Suppl 3 (2011), S953–S956.
32. Haller, O., Weber, F., The interferon response circuit in antiviral host defense. Verh. K. Acad. Geneeskd. Belg. 71:1–2 (2009), 73–86.
33. Haller, O., Kochs, G., Weber, F., The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344:1 (2006), 119–130.
34. Harcourt, B.H., Sanchez, A., Offermann, M.K., Ebola virus inhibits induction of genes by double-stranded RNA in endothelial cells. Virology 252:1 (1998), 179–188.
35. Hartman, A.L., Dover, J.E., Towner, J.S., Nichol, S.T., Reverse genetic generation of recombinant Zaire Ebola viruses containing disrupted IRF-3 inhibitory domains results in attenuated virus growth in vitro and higher levels of IRF-3 activation without inhibiting viral transcription or replication. J. Virol. 80:13 (2006), 6430–6440.
36. Hartman, A.L., Ling, L., Nichol, S.T., Hibberd, M.L., Whole-genome expression profiling reveals that inhibition of host innate immune response pathways by Ebola virus can be reversed by a single amino acid change in the VP35 protein. J. Virol. 82:11 (2008), 5348–5358.
37. Hartman, A.L., Bird, B.H., Towner, J.S., Antoniadou, Z.A., Zaki, S.R., Nichol, S.T., Inhibition of IRF-3 activation by VP35 is critical for the high level of virulence of ebola virus. J. Virol. 82:6 (2008), 2699–2704.
38. Hiscott, J., Kwon, H., Genin, P., Hostile takeovers: viral appropriation of the NF-kappaB pathway. J. Clin. Investig. 107:2 (2001), 143–151.
39. Hoffmann, H.H., Schneider, W.M., Rice, C.M., Interferons and viruses: an evolutionary arms race of molecular interactions. Trends Immunol. 36:3 (2015), 124–138.
40. Hu, Y., Park-Min, K.H., Yarilina, A., Ivashkiv, L.B., Regulation of STAT pathways and IRF1 during human dendritic cell maturation by TNF-alpha and PGE2. J. Leukoc. Biol. 84:5 (2008), 1353–1360.
41. Ilinykh, P.A., Lubaki, N.M., Widen, S.G., Renn, L.A., Theisen, T.C., Rabin, R.L., et al. Different temporal effects of Ebola virus VP35 and VP24 proteins on global gene expression in human dendritic cells. J. Virol. 89:15 (2015), 7567–7583.
42. Jones, M.E., Schuh, A.J., Amman, B.R., Sealy, T.K., Zaki, S.R., Nichol, S.T., et al. Experimental inoculation of Egyptian Rousette bats (Rousettus aegyptiacus) with viruses of the Ebolavirus and Marburgvirus genera. Viruses 7:7 (2015), 3420–3442.
43. Kash, J.C., Mühlberger, E., Carter, V., Grosch, M., Perwitasari, O., Proll, S.C., et al. Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. J. Virol. 80:6 (2006), 3009–3020.
44. Kato, H., Takeuchi, O., Sato, S., Yoneyama, M., Yamamoto, M., Matsui, K., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:7089 (2006), 101–105.
45. Kawai, T., Akira, S., TLR signaling. Cell Death Differ. 13:5 (2006), 816–825.
46. Kimberlin, C.R., Bornholdt, Z.A., Li, S., Woods, V.L. Jr., MacRae, I.J., Saphire, E.O., Ebolavirus VP35 uses a bimodal strategy to bind dsRNA for innate immune suppression. Proc. Natl. Acad. Sci. USA 107:1 (2010), 314–319.
47. Kok, K.H., Lui, P.Y., Ng, M.H., Siu, K.L., Au, S.W., Jin, D.Y., The double-stranded RNA-binding protein PACT functions as a cellular activator of RIG-I to facilitate innate antiviral response. Cell Host Microbe 9:4 (2011), 299–309.
48. Kröger, A., Köster, M., Schroeder, K., Hauser, H., Mueller, P.P., Activities of IRF-1. J. Interferon Cytokine Res. 22:1 (2002), 5–14.
49. Kuhn, J.H., Dodd, L.E., Wahl-Jensen, V., Radoshitzky, S.R., Bavari, S., Jahrling, P.B., Evaluation of perceived threat differences posed by filovirus variants. Biosecur. Bioterror. Biodef. Strateg. Pract. Sci. 9:4 (2011), 361–371.
50. Kuhn, J.H., Bào, Y., Bavari, S., Becker, S., Bradfute, S., Brauburger, K., et al. Virus nomenclature below the species level: a standardized nomenclature for filovirus strains and variants rescued from cDNA. Arch. Virol. 159:5 (2014), 1229–1237.
51. Kumar, A., Abbas, W., Herbein, G., TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy?. Mediat. Inflamm., 2013, 484378.
52. Leung, D.W., Ginder, N.D., Fulton, D.B., Nix, J., Basler, C.F., Honzatko, R.B., et al. Structure of the Ebola VP35 interferon inhibitory domain. Proc. Natl. Acad. Sci. USA 106:2 (2009), 411–416.
53. Leung, D.W., Shabman, R.S., Farahbakhsh, M., Prins, K.C., Borek, D.M., Wang, T., et al. Structural and functional characterization of Reston Ebola virus VP35 interferon inhibitory domain. J. Mol. Biol. 399:3 (2010), 347–357.
54. Leung, D.W., Prins, K.C., Borek, D.M., Farahbakhsh, M., Tufariello, J.M., Ramanan, P., et al. Structural basis for dsRNA recognition and interferon antagonism by Ebola VP35. Nat. Struct. Mol. Biol. 17:2 (2010), 165–172.
55. Li, K., Chen, Z., Kato, N., Gale, M. Jr., Lemon, S.M., Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. J. Biol. Chem. 280:17 (2005), 16739–16747.
56. Malmgaard, L., Induction and regulation of IFNs during viral infections. J. Interferon Cytokine Res. 24:8 (2004), 439–454.
57. Mateo, M., Reid, S.P., Leung, L.W., Basler, C.F., Volchkov, V.E., Ebolavirus VP24 binding to karyopherins is required for inhibition of interferon signaling. J. Virol. 84:2 (2010), 1169–1175.
58. Mateo, M., Carbonnelle, C., Reynard, O., Kolesnikova, L., Nemirov, K., Page, A., et al. VP24 is a molecular determinant of Ebola virus virulence in guinea pigs. J. Infect. Dis. 204:Suppl 3 (2011), S1011–S1020.
59. Messaoudi, I., Amarasinghe, G.K., Basler, C.F., Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus. Nat. Rev. Microbiol. 13:11 (2015), 663–676.
60. Mikkelsen, S.S., Jensen, S.B., Chiliveru, S., Melchjorsen, J., Julkunen, I., Gaestel, M., et al. RIG-I-mediated activation of p38 MAPK is essential for viral induction of interferon and activation of dendritic cells: dependence on TRAF2 and TAK1. J. Biol. Chem. 284:16 (2009), 10774–10782.
61. Palladino, M.A., Bahjat, F.R., Theodorakis, E.A., Moldawer, L.L., Anti-TNF-alpha therapies: the next generation. Nat. Rev. Drug Discov. 2:9 (2003), 736–746.
62. Pappalardo, M., Julia, M., Howard, M.J., Rossman, J.S., Michaelis, M., Wass, M.N., Conserved differences in protein sequence determine the human pathogenicity of Ebolaviruses. Sci. Rep., 6, 2016, 23743.
63. Peters, K., Chattopadhyay, S., Sen, G.C., IRF-3 activation by Sendai virus infection is required for cellular apoptosis and avoidance of persistence. J. Virol. 82:7 (2008), 3500–3508.
64. Ramanan, P., Shabman, R.S., Brown, C.S., Amarasinghe, G.K., Basler, C.F., Leung, D.W., Filoviral immune evasion mechanisms. Viruses 3:9 (2011), 1634–1649.
65. Ramanan, P., Edwards, M.R., Shabman, R.S., Leung, D.W., Endlich-Frazier, A.C., Borek, D.M., et al. Structural basis for Marburg virus VP35-mediated immune evasion mechanisms. Proc. Natl. Acad. Sci. USA 109:50 (2012), 20661–20666.
66. Reid, S.P., Valmas, C., Martinez, O., Sanchez, F.M., Basler, C.F., Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1. J. Virol. 81:24 (2007), 13469–13477.
67. Reid, S.P., Leung, L.W., Hartman, A.L., Martinez, O., Shaw, M.L., Carbonnelle, C., et al. Ebola virus VP24 binds karyopherin alpha1 and blocks STAT1 nuclear accumulation. J. Virol. 80:11 (2006), 5156–5167.
68. Reimer, T., Brcic, M., Schweizer, M., Jungi, T.W., poly(I:C) and LPS induce distinct IRF3 and NF-kappaB signaling during type-I IFN and TNF responses in human macrophages. J. Leukoc. Biol. 83:5 (2008), 1249–1257.
69. Sato, M., Hata, N., Asagiri, M., Nakaya, T., Taniguchi, T., Tanaka, N., Positive feedback regulation of type I IFN genes by the IFN-inducible transcription factor IRF-7. FEBS Lett. 441:1 (1998), 106–110.
70. Schumann, M., Gantke, T., Mühlberger, E., Ebola virus VP35 antagonizes PKR activity through its C-terminal interferon inhibitory domain. J. Virol. 83:17 (2009), 8993–8997.
71. Slenczka, W., Klenk, H.D., Forty years of Marburg virus. J. Infect. Dis. 196:Suppl 2 (2007), S131–S135.
72. Taylor, D.J., Dittmar, K., Ballinger, M.J., Bruenn, J.A., Evolutionary maintenance of filovirus-like genes in bat genomes. BMC Evolut. Biol., 11, 2011, 336.
73. Towner, J.S., Pourrut, X., Albariño, C.G., Nkogue, C.N., Bird, B.H., Grard, G., et al. Marburg virus infection detected in a common African bat. PLoS One, 2(8), 2007, e764.
74. Towner, J.S., Sealy, T.K., Khristova, M.L., Albariño, C.G., Conlan, S., Reeder, S.A., et al. Newly discovered ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog., 4(11), 2008, e1000212.
75. Towner, J.S., Amman, B.R., Sealy, T.K., Carroll, S.A., Comer, J.A., Kemp, A., et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog., 5(7), 2009, e1000536.
76. Valmas, C., Basler, C.F., Marburg virus VP40 antagonizes interferon signaling in a species-specific manner. J. Virol. 85:9 (2011), 4309–4317.
77. Valmas, C., Grosch, M.N., Schümann, M., Olejnik, J., Martinez, O., Best, S.M., et al. Marburg virus evades interferon responses by a mechanism distinct from ebola virus. PLoS Pathog., 6(1), 2010, e1000721.
78. Wang, J., Basagoudanavar, S.H., Wang, X., Hopewell, E., Albrecht, R., García-Sastre, A., et al. NF-kappa B RelA subunit is crucial for early IFN-beta expression and resistance to RNA virus replication. J. Immunol. 185:3 (2010), 1720–1729.
79. Wong, G., Kobinger, G.P., Qiu, X., Characterization of host immune responses in Ebola virus infections. Expert Rev. Clin. Immunol. 10:6 (2014), 781–790.
80. Yarilina, A., Ivashkiv, L.B., Type I interferon: a new player in TNF signaling. Curr. Dir. Autoimmun. 11 (2010), 94–104.
81. Ye, J., Maniatis, T., Negative regulation of interferon-beta gene expression during acute and persistent virus infections. PloS One, 6(6), 2011, e20681.
82. Yen, B., Mulder, L.C., Martinez, O., Basler, C.F., Molecular basis for ebolavirus VP35 suppression of human dendritic cell maturation. J. Virol. 88:21 (2014), 12500–12510.
83. Zaritsky, L.A., Bedsaul, J.R., Zoon, K.C., Virus multiplicity of infection affects type I interferon subtype induction profiles and interferon-stimulated genes. J. Virol. 89:22 (2015), 11534–11548.
84. Zhang, A.P., Abelson, D.M., Bornholdt, Z.A., Liu, T., Woods, V.L. Jr., Saphire, E.O., The ebolavirus VP24 interferon antagonist: know your enemy. Virulence 3:5 (2012), 440–445.
85. Zhang, A.P., Bornholdt, Z.A., Liu, T., Abelson, D.M., Lee, D.E., Li, S., et al. The ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathog., 8(2), 2012, e1002550.
86. Zinzula, L., Tramontano, E., Strategies of highly pathogenic RNA viruses to block dsRNA detection by RIG-I-like receptors: hide, mask, hit. Antivir. Res. 100:3 (2013), 615–635.